Patients with a previous history of hypersensitivity reaction (HSR) to iodinated contrast media (ICM) are at high risk of the development of HSR to ICM. Many studies have tried to evaluate the diagnostic potential of skin tests in this population but have not yet reached a common conclusion. We investigated the role of skin tests in patients with HSR to ICM in terms of positive rate, cross‐reactivity rate, and tolerability to skin test‐negative ICM according to the type of HSR.

We performed literature searches of the MEDLINE and EMBASE databases and included studies where skin tests were performed in patients with HSR to ICM, with extractable outcomes. Outcomes were pooled using a random‐effects model.

Twenty‐one studies were included. Pooled per‐patient positive rates of skin tests were 17% (95% CI, 10–26%) in patients with immediate HSR, and up to 52% (95% CI, 31–72%) when confined to severe immediate HSR. Among patients with nonimmediate HSR, the positive rate was 26% (95% CI, 15–41%). The pooled per‐patient cross‐reactivity rate was higher in nonimmediate HSR (68%; 95% CI, 48–83%) than that in immediate HSR (39%; 95% CI, 29–50%). Median per‐test cross‐reactivity rates between pairs of ICM were 7% (IQR, 6–9%) in immediate HSR and 38% (IQR, 22–51%) in nonimmediate HSR. Pooled per‐patient recurrence rates of HSR to skin test‐negative ICM were 7% (95% CI, 4–14%) in immediate HSR and 35% (95% CI, 19–55%) in nonimmediate HSR.

Skin tests may be helpful in diagnosing and managing patients with HSR to ICM, especially in patients with severe immediate HSR.